Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Congenital Abnormalities 1

Interventions

Cytarabine 7Idarubicin 3Etoposide 3Daunorubicin 3Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Methotrexate 2Cyclophosphamide 2Clofarabine 2valspodar 1tipifarnib 1pegylated granulocyte colony-stimulating factor 1fludarabine phosphate 1enasidenib 1aldesleukin 1Whole-Body Irradiation 1Vorinostat 1Topotecan 1Pravastatin 1Mycophenolic Acid 1Mitoxantrone 1Lenalidomide 1Gemtuzumab 1Cyclosporine 1Calicheamicins 1Busulfan 1Bortezomib 1Bone Marrow Transplantation 1Biopsy 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Monocytic, Acute × Calicheamicins × Clear all
NCT00895934 2019-05-23

Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML

National Cancer Institute (NCI)

Phase 1/2 Completed
52 enrolled 12 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡